Department of Biotechnology and Bioinformatics, School of Life Sciences, JSS Academy of Higher Education and Research, Mysuru, Karnataka, India.
Department of Biotechnology, Teresian College, Mysuru, Karnataka, India.
J Pharm Pharmacol. 2022 May 20;74(5):681-710. doi: 10.1093/jpp/rgab098.
We aim to provide a critical review focused on the various pharmacological activities of Azadirachta indica A. Juss related to diabetes management. We also emphasise on phytochemistry and toxicology of A. indica, which could provide a comprehensive approach for plant-based drug development in future.
From 2784 identified studies, only 83 were considered after double screening based on the inclusion criteria. Further, 63 pharmacological investigations were considered for review. Resultant studies deliberated on using different extracts and phytochemicals of A. indica on blood glucose level, lipid profile, oxidative stress, carbohydrate digestion enzymes, diabetic complications, glucose tolerance, and uptake of glucose.
In the end, one can know the efficacy of A. indica as a potent antidiabetic herbal medicine. However, based on gaps in research, recommendations have been provided to evaluate A. indica. in a systematic manner to develop plant-based drugs, nutraceuticals, and to evaluate their clinical efficiency and safety against diabetes mellitus.
我们旨在提供一项重点关注印楝（Azadirachta indica A. Juss）与糖尿病管理相关的各种药理学活性的批判性综述。我们还强调了印楝的植物化学和毒理学，这为未来基于植物的药物开发提供了一种全面的方法。
在已确定的 2784 项研究中，仅在基于纳入标准进行双重筛选后考虑了 83 项。此外，还对 63 项药理学研究进行了综述。结果研究讨论了使用印楝的不同提取物和植物化学物质对血糖水平、血脂谱、氧化应激、碳水化合物消化酶、糖尿病并发症、葡萄糖耐量和葡萄糖摄取的影响。
最终，可以了解印楝作为一种有效的抗糖尿病草药的功效。然而，基于研究中的差距，提出了建议，以系统地评估印楝，开发基于植物的药物、营养保健品，并评估它们对糖尿病的临床疗效和安全性。
